Taysha Gene Therapies (TSHA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.11
- Surprise
- —
- Score today
- 4.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates TSHA Sell at 4.7/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Pipeline: TSHA-102
- Concentration risk — Counterparty: UT Southwestern
- DATA_ISSUE: analyst_target_implausible (raw $13.00 vs price $3.56 — ratio 3.7×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.56
- Price target
- $5.35
- Stop
- $3.36
- Upside to target
- +50.5%
Risk check: RSI 20 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
TSHA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.17B
- P/E (fwd)
- -7.7
- 52-week range
- $3.55–$7.30
- Off 52-week high
- 51.3%
- RSI (14)
- 20
- Volume vs avg
- 0.35×
- Score today
- 4.7/10